Seelos therapeutics announces proposed public offering of common stock

New york, may 19, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (cns) disorders and rare diseases, announced today that it has commenced an underwritten public offering of shares of common stock. the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
SEEL Ratings Summary
SEEL Quant Ranking